Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.
Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.
复制标题
行动呼吁：了解SGLT-2抑制剂和GLP-1受体激动剂的使用差异。
DOI：
10.1016/j.ajpc.2023.100477
复制
发表时间：
2023-03
影响因子：
4.1
通讯作者：
Shah, Nishant P
中科院分区：
文献类型：
--
作者：
Khedagi, Apurva;Hoke, Cara;Kelsey, Michelle;Coviello, Andrea;Jones, W Schuyler;Jackson, Larry R 2nd;Patel, Manesh R;McGarrah, Rob W;Pagidipati, Neha J;Shah, Nishant P
心血管疾病仍然是最突出的全球健康问题之一，并已被证明会对某些社区造成危害。尽管人们为改善健康不平等做出了越来越多的集体努力，但众多差异继续影响心血管结局。心血管疾病预防中最突出的差异是钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂和胰高血糖素样肽1（GLP-1）受体激动剂的使用和分布。几项具有里程碑意义的试验已经证明了这些新型药物的疗效，不仅在糖尿病患者中预防心血管疾病，而且在心力衰竭和慢性肾脏疾病中也是如此。然而，由于某些种族/族裔、性别和社会经济群体的差异，这些药物的使用仍然受到限制。本综述旨在强调和理解心血管疾病预防关键药物SGLT-2抑制剂和GLP-1激动剂的使用和处方模式的差异。我们的目标是丰富理解和激励努力结束心血管疾病发病率和死亡率的差距，由于种族，性别和收入不平等。
Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Among the most prominent disparities within cardiovascular disease prevention are with the use and distribution of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. Several landmark trials have demonstrated the efficacy of these novel agents, not only in cardiovascular disease prevention among those with diabetes, but also in heart failure and chronic kidney disease. However, the use of these agents remains limited by disparities in certain racial/ethnic, sex, and socioeconomic groups. This review works to highlight and understand these differences on the use and prescribing patterns of pivotal agents in cardiovascular disease prevention, SGLT-2 inhibitors and GLP-1 agonists. Our aim is to enrich understanding and to inspire efforts to end disparities in cardiovascular morbidity and mortality due to race, sex and income inequality.